Research Advance on the Role of Spleen Tyrosine Kinase Inhibitors in Hematologic Malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1054-1058, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-827162
ABSTRACT
Abstract Spleen tyrosine kinase (SYK) is not only a key kinase in the B-cell receptor (BCR) signaling pathway, but also a critical component of other signal transduction pathways such as Fc receptor, complement receptor and integrin. Abnormal activation of SYK closely related to the occurrence and development of hematological malignancies, thus targeting SYK has become a research hotspot. Several SYK inhibitors including Fostamatinib, Entospletinib and Cerdulatinib were being evaluated in clincal trials. As a second generation SYK inhibitor, Entospletinib has achieved good efficacy in lymphoid and myeloid hematologic tumors. Furthermore, Entospletinib can significantly relieve hematopoietic stem cell transplantation(HCT) related graft versus host disease (GVHD). In this review the role of SYK inhibitors in treatment of hematological malignancies is summarized brifely.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Bazo
/
Neoplasias Hematológicas
/
Inhibidores de Proteínas Quinasas
/
Quinasa Syk
/
Enfermedad Injerto contra Huésped
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS